Scoping review of plant-derived senotherapeutics: 111 preclinical studies, 2015–2025
A scoping review mapped 111 preclinical studies (2015–2025) on plant-derived senotherapeutics, describing senolytic and senomorphic mechanisms and metabolomics-guided discovery; pharmacokinetics and methodological heterogeneity remain unresolved. [1]
Automatic summary · not editorially reviewed
The key findings
The scoping review followed Joanna Briggs Institute guidelines and PRISMA-ScR and included 111 of 1355 identified articles on plant-derived senotherapeutics published 2015–2025. [1]
Reported senolytic mechanisms included BCL-2/BCL-XL apoptosis, PI3K/AKT/mTOR and p53/p21/p16 modulation, while NF-κB-mediated SASP suppression predominated among senomorphic agents. [1]
Challenges in pharmacokinetic optimization and methodological heterogeneity in senescence induction and biomarker panels persist, and clinical validation remains a stated outlook. [1]
The source at a glance
- Study type / format
- Scoping review of preclinical evidence (abstract)
- Population / context
- Preclinical studies of plant-derived senotherapeutics published 2015–2025
- Summary based on
- Study abstract
- Original publication
- August 11, 2026
Scoping review of 111 preclinical plant senotherapy studies
The review followed Joanna Briggs Institute guidelines and PRISMA-ScR and searched PubMed, Scopus, Web of Science, Wiley Library and Google Scholar for preclinical evidence published between 2015 and 2025. Of 1355 identified articles, 111 studies met the inclusion criteria. The most characterized compound classes were flavonoids, non-flavonoid polyphenols and stilbenes, terpenoids and alkaloids, and combination and complex plant extracts. The authors frame plant-derived agents as alternatives motivated by concerns about off-target effects of synthetic senolytics.
Supporting source [1]
Senolytic and senomorphic mechanisms plus metabolomics guidance
As senolytic mechanisms, the review reports BCL-2/BCL-XL apoptosis, PI3K/AKT/mTOR and p53/p21/p16 modulation; NF-κB-mediated suppression of the senescence-associated secretory phenotype predominated among senomorphic agents. Ginkgetin-mediated inhibition of the cGAS-STING pathway was identified as a mechanistically novel target. Metabolomics served two roles: guiding compound discovery from complex plant matrices, such as phenolamides from Allium hookeri, and validating mechanisms by characterizing senescence-associated metabolic remodeling, including restored retinoic acid metabolism, attenuated lipotoxic metabolites, and regulation of the tricarboxylic acid cycle and a choline-betaine-TCA cascade.
Supporting source [1]
Preclinical scope: pharmacokinetics and heterogeneity unresolved
The mapped evidence is preclinical. The authors state that challenges in pharmacokinetic optimization and methodological heterogeneity in senescence induction and biomarker panels persist. They describe metabolomics-guided plant-derived senotherapy as a foundation for progression toward clinical validation and functional food applications for healthy aging and age-related disease management; this is a stated outlook, not demonstrated clinical benefit.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This is a scoping review of preclinical studies, so no human efficacy or safety is established, and the clinical and functional-food outlook is the authors' perspective.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Hussin NMH, Mediani A, Abd Latip N, Fenech M, Widyanto RM, Sharif R. · europepmc.org · August 11, 2026